ScholarIQanswers from OpenAlex & ORCID
You Lü
ResearcherPublications, citations & collaboration network
You Lü is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does You Lü have?
ScholarIQindexed works
You Lü has 430 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does You Lü have?
ScholarIQcitation count
You Lü has 12,414 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of You Lü?
ScholarIQh-index
You Lü has an h-index of 53 in OpenAlex.
What is the i10-index of You Lü?
ScholarIQi10-index
You Lü has an i10-index of 176 in OpenAlex.
What is the ORCID of You Lü?
ScholarIQorcid
The ORCID for You Lü is on the source record.
What is the OpenAlex record for You Lü?
ScholarIQopenalex
The OpenAlex for You Lü is on the source record.
What are the most-cited papers on You Lü?
ScholarIQmost cited works
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Guangping Gao, Luk H. Vandenberghe, Mauricio R. Alvira, You Lü, Roberto Calcedo, Xiangyang Zhou, James M. Wilson
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
You Lü, Jianxin Xue, Tao Deng, Xiaojuan Zhou, Kun Yu, Lei Deng, Meijuan Huang, Xin Yi, Maozhi Liang, Yu Wang, Haige Shen, Ruizhan Tong, Wenbo Wang, Li Li, Jin Sook Song, Jing Li, Xiaoxing Su, Zhenyu Ding, Youling Gong, Jiang Zhu, Yongsheng Wang, Bingwen Zou, Yan Zhang, Yanying Li, Lin Zhou, Yongmei Liu, Min Yu, Yuqi Wang, Xuanwei Zhang, Limei Yin, Xuefeng Xia, Yong Zeng, Qiao Zhou, Binwu Ying, Chong Chen, Yuquan Wei, Weimin Li, Tony Mok
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa, Sang-We Kim, Jin-Ji Yang, Myung‐Ju Ahn, Jie Wang, James Chih‐Hsin Yang, You Lü, Shinji Atagi, Santiago Ponce, Ki Hyeong Lee, Yunpeng Liu, Kiyotaka Yoh, Jianying Zhou, Xiaojin Shi, Alan Webster, Haiyi Jiang, Tony Mok
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li, Yong Song, Jifeng Feng, Juan Li, Zhiyong He, Rui Zhou, Weimin Li, You Lü, Yingyi Wang, Lijun Wang, Nong Yang, Yan Zhang, Zhuang Yu, Yanqiu Zhao, Conghua Xie, Ying Cheng, Hui Zhou, Shuyan Wang, Donglei Zhu, Wen Zhang, Li Zhang
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Xiaoqing Liu, Yunzhong Zhu, Shun Lü, Jifeng Feng, Jianxing He, Baohui Han, Jie Wang, Guoliang Jiang, Chunhong Hu, Hao Zhang, Gang Cheng, Xiangqun Song, You Lü, Hongming Pan, Wenjuan Zheng, Anny-Yue Yin